The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trial

Evelynne S. Fulda(Cancer Research And Biostatistics), Kathleen V. Fitch(Harvard University), Heather J. Ribaudo(Cancer Research And Biostatistics), Carl J. Fichtenbaum(Cancer Research And Biostatistics), Mark Byroads(Harvard University), Regina Harden(University of Illinois Chicago), Heather Sprenger(Frontier Science & Technology Research Foundation, Inc.), Gregory K. Robbins(Harvard University), Rita Lira(Hospital Nossa Senhora da Conceição), Kayla Paradis(Cancer Research And Biostatistics), Pamela S. Douglas(Duke University), Steven Grinspoon(Massachusetts General Hospital), Michael T. Lu(Cancer Research And Biostatistics), Sylvia Davila Nieves(University of Puerto Rico, Medical Sciences Campus), Jorge Leon Cruz(Cancer Research And Biostatistics), Triin Umbleja(Harvard University), Baiba Berzins(Northwestern University), Carlos Malvestutto(The Ohio State University Wexner Medical Center), Emma M. Kileel(Boston University), Sandra Wagner Cardoso(Instituto Evandro Chagas), Sara McCallum(Cancer Research And Biostatistics), Judith A. Aberg(Icahn School of Medicine at Mount Sinai), M. Elena Martinez(The University of Texas Health Science Center), Ken Wood(Frontier Science & Technology Research Foundation, Inc.), Markella V. Zanni(Harvard University), Françoise Giguel(Harvard University), Frederic Bone
Contemporary Clinical Trials
November 30, 2022
Cited by 3


Related Papers